Which has better earnings and valuation, BVS or CV?

Bioventus has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.90 $22.73M $0.77 16.64 CapsoVision $13.55M 24.40 -$25.32M -$0.47 N/A

Is BVS or CV more profitable?

Bioventus has a net margin of 9.36% compared to CapsoVision's net margin of -214.74%. Bioventus' return on equity of 28.08% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% CapsoVision -214.74% -177.85% -135.07%

Is CV or ENOV more profitable?

Enovis has a net margin of -47.96% compared to CapsoVision's net margin of -214.74%. Enovis' return on equity of 12.03% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% Enovis -47.96% 12.03% 4.91%

Which has better earnings & valuation, IRMD or CV?

iRadimed has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 12.51 $22.48M $1.79 45.80 CapsoVision $13.55M 24.40 -$25.32M -$0.47 N/A

Is IRMD or CV more profitable?

iRadimed has a net margin of 26.70% compared to CapsoVision's net margin of -214.74%. iRadimed's return on equity of 23.45% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% CapsoVision -214.74% -177.85% -135.07%

Is CBLL or CV more profitable?

CeriBell has a net margin of -64.73% compared to CapsoVision's net margin of -214.74%. CeriBell's return on equity of -44.85% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -64.73% -44.85% -35.69% CapsoVision -214.74% -177.85% -135.07%

CapsoVision (CV) Competitors

$6.60 +0.10 (+1.46%)

As of 10:02 AM Eastern

Compare

CV vs. BVS, STAA, ENOV, IRMD, and CBLL

Should you buy CapsoVision stock or one of its competitors? CapsoVision's main competitors and comparable companies include Bioventus (BVS), STAAR Surgical (STAA), Enovis (ENOV), iRadimed (IRMD), and CeriBell (CBLL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does CapsoVision compare to Bioventus?

Bioventus (NASDAQ:BVS) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Bioventus has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.90	$22.73M	$0.77	16.64
CapsoVision	$13.55M	24.40	-$25.32M	-$0.47	N/A

Bioventus has a net margin of 9.36% compared to CapsoVision's net margin of -214.74%. Bioventus' return on equity of 28.08% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
CapsoVision	-214.74%	-177.85%	-135.07%

Bioventus presently has a consensus price target of $16.80, indicating a potential upside of 31.10%. CapsoVision has a consensus price target of $9.50, indicating a potential upside of 43.83%. Given CapsoVision's higher probable upside, analysts clearly believe CapsoVision is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

62.9% of Bioventus shares are owned by institutional investors. 33.5% of Bioventus shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bioventus has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, CapsoVision has a beta of -2.47, meaning that its stock price is 347% less volatile than the broader market.

In the previous week, Bioventus had 1 more articles in the media than CapsoVision. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.89 beat Bioventus' score of 1.23 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
Bioventus	Positive
CapsoVision	Very Positive

Summary

Bioventus beats CapsoVision on 13 of the 16 factors compared between the two stocks.

How does CapsoVision compare to STAAR Surgical?

CapsoVision (NASDAQ:CV) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

STAAR Surgical has a net margin of 1.13% compared to CapsoVision's net margin of -214.74%. STAAR Surgical's return on equity of 9.05% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
STAAR Surgical	1.13%	9.05%	6.99%

CapsoVision has higher earnings, but lower revenue than STAAR Surgical. CapsoVision is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	24.40	-$25.32M	-$0.47	N/A
STAAR Surgical	$339.59M	3.35	-$80.45M	$0.07	323.64

CapsoVision currently has a consensus target price of $9.50, indicating a potential upside of 43.83%. STAAR Surgical has a consensus target price of $28.40, indicating a potential upside of 25.36%. Given CapsoVision's stronger consensus rating and higher probable upside, analysts plainly believe CapsoVision is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
STAAR Surgical	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

In the previous week, STAAR Surgical had 10 more articles in the media than CapsoVision. MarketBeat recorded 11 mentions for STAAR Surgical and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.89 beat STAAR Surgical's score of 0.41 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
STAAR Surgical	Neutral

CapsoVision has a beta of -2.47, suggesting that its share price is 347% less volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

96.7% of STAAR Surgical shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 39.9% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

STAAR Surgical beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does CapsoVision compare to Enovis?

CapsoVision (NASDAQ:CV) and Enovis (NYSE:ENOV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

CapsoVision has a beta of -2.47, meaning that its stock price is 347% less volatile than the broader market. Comparatively, Enovis has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

98.4% of Enovis shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Enovis has a net margin of -47.96% compared to CapsoVision's net margin of -214.74%. Enovis' return on equity of 12.03% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
Enovis	-47.96%	12.03%	4.91%

CapsoVision has higher earnings, but lower revenue than Enovis. CapsoVision is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	24.40	-$25.32M	-$0.47	N/A
Enovis	$2.30B	0.44	-$1.18B	-$19.26	N/A

In the previous week, Enovis had 9 more articles in the media than CapsoVision. MarketBeat recorded 10 mentions for Enovis and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.89 beat Enovis' score of 0.80 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
Enovis	Positive

CapsoVision presently has a consensus price target of $9.50, indicating a potential upside of 43.83%. Enovis has a consensus price target of $40.38, indicating a potential upside of 130.97%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Enovis beats CapsoVision on 12 of the 16 factors compared between the two stocks.

How does CapsoVision compare to iRadimed?

iRadimed (NASDAQ:IRMD) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

iRadimed currently has a consensus price target of $120.00, indicating a potential upside of 46.38%. CapsoVision has a consensus price target of $9.50, indicating a potential upside of 43.83%. Given iRadimed's stronger consensus rating and higher possible upside, research analysts clearly believe iRadimed is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

iRadimed has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	12.51	$22.48M	$1.79	45.80
CapsoVision	$13.55M	24.40	-$25.32M	-$0.47	N/A

iRadimed has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, CapsoVision has a beta of -2.47, meaning that its share price is 347% less volatile than the broader market.

iRadimed has a net margin of 26.70% compared to CapsoVision's net margin of -214.74%. iRadimed's return on equity of 23.45% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
CapsoVision	-214.74%	-177.85%	-135.07%

92.3% of iRadimed shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 2.3% of CapsoVision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, iRadimed had 3 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for iRadimed and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.89 beat iRadimed's score of 0.85 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
iRadimed	Positive
CapsoVision	Very Positive

Summary

iRadimed beats CapsoVision on 15 of the 17 factors compared between the two stocks.

How does CapsoVision compare to CeriBell?

CeriBell (NASDAQ:CBLL) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

CeriBell presently has a consensus target price of $24.40, suggesting a potential upside of 1.52%. CapsoVision has a consensus target price of $9.50, suggesting a potential upside of 43.83%. Given CapsoVision's higher possible upside, analysts clearly believe CapsoVision is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

CeriBell has a net margin of -64.73% compared to CapsoVision's net margin of -214.74%. CeriBell's return on equity of -44.85% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
CapsoVision	-214.74%	-177.85%	-135.07%

CeriBell has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, CapsoVision has a beta of -2.47, suggesting that its stock price is 347% less volatile than the broader market.

In the previous week, CeriBell had 8 more articles in the media than CapsoVision. MarketBeat recorded 9 mentions for CeriBell and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.89 beat CeriBell's score of 0.40 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
CeriBell	Neutral
CapsoVision	Very Positive

CapsoVision has lower revenue, but higher earnings than CeriBell. CapsoVision is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	10.36	-$53.41M	-$1.76	N/A
CapsoVision	$13.55M	24.40	-$25.32M	-$0.47	N/A

Summary

CeriBell beats CapsoVision on 10 of the 15 factors compared between the two stocks.

Get CapsoVision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CV vs. The Competition

Export

Metric	CapsoVision	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$330.28M	$5.39B	$7.15B	$14.21B
Dividend Yield	N/A	1.80%	2.57%	11.71%
P/E Ratio	-14.04	24.87	273.46	25.34
Price / Sales	24.40	83.09	670.93	98.74
Price / Cash	N/A	33.03	28.42	34.96
Price / Book	23.59	5.99	10.43	6.20
Net Income	-$25.32M	$149.33M	$3.48B	$357.95M
7 Day Performance	3.85%	-1.81%	-1.90%	-1.21%
1 Month Performance	2.24%	-3.67%	-0.14%	-3.22%
1 Year Performance	52.54%	9.21%	19.12%	6.27%

CapsoVision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CV CapsoVision	3.1593 of 5 stars	$6.61 +1.5%	$9.50 +43.8%	+58.0%	$330.28M	$13.55M	N/A	99	Positive News High Trading Volume
BVS Bioventus	4.2867 of 5 stars	$14.07 flat	$16.80 +19.4%	+82.0%	$1.18B	$568.09M	18.27	1,200	Positive News
STAA STAAR Surgical	3.3663 of 5 stars	$23.47 flat	$28.40 +21.0%	-16.7%	$1.18B	$239.44M	335.33	1,211	High Trading Volume
ENOV Enovis	3.6477 of 5 stars	$18.58 +0.1%	$40.38 +117.3%	-42.9%	$1.07B	$2.25B	N/A	7,802	Analyst Upgrade
IRMD iRadimed	3.2634 of 5 stars	$83.45 flat	$120.00 +43.8%	+15.8%	$1.07B	$83.81M	46.62	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CV) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CapsoVision (CV) Competitors

CV vs. BVS, STAA, ENOV, IRMD, and CBLL

How does CapsoVision compare to Bioventus?

Summary

How does CapsoVision compare to STAAR Surgical?

Summary

How does CapsoVision compare to Enovis?

Summary

How does CapsoVision compare to iRadimed?

Summary

How does CapsoVision compare to CeriBell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CapsoVision (CV) Competitors

CV vs. BVS, STAA, ENOV, IRMD, and CBLL

How does CapsoVision compare to Bioventus?

Which has better earnings and valuation, BVS or CV?

Is BVS or CV more profitable?

Do analysts prefer BVS or CV?

Do insiders and institutionals believe in BVS or CV?

Which has more volatility & risk, BVS or CV?

Does the media refer more to BVS or CV?

Summary

How does CapsoVision compare to STAAR Surgical?

Is CV or STAA more profitable?

Which has stronger earnings & valuation, CV or STAA?

Do analysts prefer CV or STAA?

Does the media prefer CV or STAA?

Which has more volatility & risk, CV or STAA?

Do institutionals and insiders believe in CV or STAA?

Summary

How does CapsoVision compare to Enovis?

Which has more volatility and risk, CV or ENOV?

Do institutionals and insiders have more ownership in CV or ENOV?

Is CV or ENOV more profitable?

Which has higher earnings and valuation, CV or ENOV?

Does the media prefer CV or ENOV?

Do analysts recommend CV or ENOV?

Summary

How does CapsoVision compare to iRadimed?

Do analysts prefer IRMD or CV?

Which has better earnings & valuation, IRMD or CV?

Which has more volatility and risk, IRMD or CV?

Is IRMD or CV more profitable?

Do institutionals & insiders believe in IRMD or CV?

Does the media favor IRMD or CV?

Summary

How does CapsoVision compare to CeriBell?

Do analysts rate CBLL or CV?

Is CBLL or CV more profitable?

Which has more risk and volatility, CBLL or CV?

Does the media prefer CBLL or CV?

Which has higher earnings & valuation, CBLL or CV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools